Complement Receptor 2 (CR2/CD21) is a critical linkage point between innate and adaptive immunity, serving as a primary receptor for complement fragments (C3d, C3dg, iC3b) and the Epstein-Barr virus (EBV) glycoprotein gp350/220. TarMart provides high-specification reagents designed to accelerate your CD21-targeted drug discovery pipelines.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD21 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD21 Extracellular Domain (ECD) Fusion Protein HEK293 expressed for native glycosylation. High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. Suitable for binding affinity and ligand competition assays. |
View CD21 Products |
| Gene Delivery | CD21 Lentivirus Premade Particles Full-length human CD21 (CR2) ORF for stable cell line generation. Essential for cell-based flow cytometry and functional assays. |
View CD21 Products |
| Benchmark Ab | Anti-CD21 Recombinant Monoclonal Antibody Sequence-derived from established clinical/diagnostic clones. Perfect as a positive control in ELISA, FACS, and ligand blocking assays. |
View CD21 Products |
| Validator | CD21 siRNA Set Target-specific knockdown pool to validate target specificity and downstream signaling pathways. |
View CD21 Products |
| Related Target A | CD19 CD21 forms a signaling complex with CD19 and CD81 on mature B cells, significantly lowering the threshold for B-cell activation. |
View CD19 Products |
| Related Target B | CD81 Crucial component of the CD19/CD21/CD81 co-receptor complex involved in B-cell signaling and activation pathways. |
View CD81 Products |
| Related Target C | C3d The primary complement ligand for CD21. Essential for validating CR2-targeted complement inhibitors and fusion proteins. |
View C3d Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Epitope Specificity (SCR1-2 Domain Targeting) | Truncated and full-length CD21 ECD proteins strictly verified by mass spectrometry and sequence analysis to ensure correct folding of Short Consensus Repeats (SCRs). |
| Cross-Species Reactivity Verification | Human, Cynomolgus, and Rodent ortholog proteins available with >95% purity to facilitate preclinical safety and efficacy profiling. |
| Lack of Reliable Reference Controls | Clinical benchmark antibodies and sequence-verified positive controls included in the catalog. |
| Off-Target Binding & False Positives | High-purity expression in mammalian cells (HEK293) minimizes non-specific glycan-mediated background binding. |
Live CD21/CR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD21 (Complement Receptor 2) is expanding rapidly. Beyond its classical role as a biomarker for B-cell lymphomas, CD21 is a pivotal node connecting the complement system and adaptive immunity. The race for CD21 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-functional fusion proteins and antibody-drug conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting localized complement regulation and selective B-cell modulation to treat autoimmune disorders and complement-mediated kidney diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Complement Fusion Proteins (e.g., CR2-FH / TT30) | Alexion Pharmaceuticals, Amyndas Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria (PNH), Glomerulonephritis, Dry AMD | Ligand-binding assays (C3d vs CD21 ECD-Fc) to verify complement-targeting efficiency. |
| Monoclonal Antibodies (Blocking) | Academic Institutes, Biopharma Startups | Epstein-Barr Virus (EBV) Infection, Autoimmune Diseases (SLE) | Viral gp350/220 or C3d competition assays requiring sequence-verified CD21 antigens. |
| Antibody-Drug Conjugates (ADCs) | Oncology-focused Biotech companies | B-cell Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma (NHL) | Internalization assays requiring high-conformation mammalian-expressed CD21 ECD. |